KREMPA DAVID (Chief Business Officer) sold 5.3% of their position (34K shares) of ETON PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $504.3K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 6/16/2025ACC: 0001437749-25-020518
Officer· Chief Business Officer
Since Mar 2023
-34K
Net shares
Net seller
$504.3K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
34K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−16.98K
Price / share
$14.92
Trade value
$253.30K
% of position
2.6%
6/12/2025
646.65K→629.67K
Common Stock
Direct
Shares
−6.80K
Price / share
$14.77
Trade value
$100.44K
% of position
1.1%
6/13/2025
629.67K→622.87K
Common Stock
Direct
Shares
−10.22K
Price / share
$14.73
Trade value
$150.58K
% of position
1.6%
6/16/2025
622.87K→612.65K
Total
Net shares
−34K
Net value
-$504.32K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/12/2025 | S · Sale | −16.98K | $14.92 | $253.30K | 2.6% | 646.65K | 629.67K |
| Common Stock Direct | 6/13/2025 | S · Sale | −6.80K | $14.77 | $100.44K | 1.1% | 629.67K | 622.87K |
| Common Stock Direct | 6/16/2025 | S · Sale | −10.22K | $14.73 | $150.58K | 1.6% | 622.87K | 612.65K |
| Total | −34K | -$504.32K | ||||||
Derivative Transactions0
No derivative transactions reported